AULBIO
- Biotech or pharma, therapeutic R&D
[Long-acting GLP-1 RA Obesity Treatment]
AULBIO is developing a long-acting injectable treatment for obesity, diabetes, dementia, schizophrenia, and prostate cancer that is administered once a month or once a quarter.
Specifically, by utilizing the GLP-1 RA based drugs and AULBIO’s proprietary technology platform for "large-scale production capable advanced microfluidics technology,"we are conducting research to develop a long-acting injectable treatment.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}